Do statins reduce the risk of infection?

BMJ 2011; 343 doi: http://dx.doi.org/10.1136/bmj.d7134 (Published 29 November 2011) Cite this as: BMJ 2011;343:d7134
  1. Beatrice A Golomb, associate professor of medicine
  1. 1Department of Medicine, UCSD School of Medicine, La Jolla, CA 92093-0995, USA
  1. bgolomb{at}ucsd.edu

Observational evidence of a benefit is now refuted by randomised trials

The linked meta-analysis of randomised trials by van den Hoek and colleagues (doi:10.1136/bmj.d7281) assesses whether the potential of statins to lower the risk of infections noted in observational studies is causal.1 Data were pooled from 11 eligible clinical trials of statins relative to placebo, all of which had at least 100 patients who were treated for at least a year. The trials studied 30 947 patients, of whom 4655 reported an infection—2368 in the statin group and 2287 in the placebo group. This new analysis—the strongest to date on this subject—showed no benefit of statins on the occurrence of infection (relative risk 1.0) or death as a result of infection.

These findings might seem surprising. They are in stark contrast to the favourable associations—greater than 60% reductions for some infection outcomes—reported in pooled analyses of mainly observational studies,2 which were also supported by mechanisms by which statins could theoretically reduce infection.

However, observational studies have reported improvements in other outcomes with statins (including bone health, cognition and Alzheimer’s …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial